$BIAFJul 22, 2026, 12:08 PMAI processed
BIAF inks deal with Pictor to develop high‐throughput sputum diagnostics for asthma/COPD
AI Summary
BioAffinity Technologies (BIAF / BIAFW) announced a collaboration with Pictor to combine bioAffinity’s sputum flow‐cytometry platform with Pictor’s targeted proteomics to develop next‐generation diagnostics for asthma and COPD, initially offered as CLIA Laboratory Developed Tests. The multi‐analyte tests are designed to profile immune cell populations and cytokine signatures to help match patients to targeted therapies (including biologics), lower per‐test cost and increase lab throughput; bioAffinity will own IP arising from the tests while Pictor retains its platform IP.
Positives
- Combines flow cytometry and targeted proteomics to enable multi‑analyte, higher‑throughput testing
- Plans to launch tests as CLIA LDTs, which can accelerate initial commercialization
- bioAffinity will own intellectual property from tests developed under the collaboration
Negatives
- Tests are still in development with no clinical/validation data disclosed
- Regulatory risk exists if LDT oversight changes or FDA clearance becomes required
- Commercial success depends on partnership execution and lab adoption of the new workflow